RB1 and glioblastoma: In non-TCGA patients with glioblastoma, receipt of chemotherapy (HR: 0.20), methylated MGMT (HR: 0.42), 21q loss (HR: 0.54), 19q gain (HR: 0.72), and RB1 alteration (HR: 0.77) positively affected survival.